Key result
Anthracycline-based chemotherapy in breast cancer patients significantly decreased right ventricular fractional area change from 48.3% to 42.1% and worsened right ventricular longitudinal strain.
Why the study?
Does anthracycline-based chemotherapy deteriorate right heart function in breast cancer patients?
Observational (n=49)
No
Does anthracycline-based chemotherapy deteriorate right heart function in breast cancer patients?
Absolute Event Rate: 42.1% vs 48.3%
p-value: p=0.01
Anthracycline-based chemotherapy in breast cancer patients is associated with significant deterioration in right ventricular function and right atrial enlargement, suggesting right heart parameters may serve as early markers of cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Suggests RV monitoring during anthracycline therapy in breast cancer; leaves open prognostic value and need for prospective validation.
Boczar et al. (2016) conducted an observational in Breast cancer (n=49). Anthracycline-based chemotherapy vs. Baseline (pre-chemotherapy) was evaluated on Right ventricular fractional area change (RV FAC) (p=0.01). Anthracycline-based chemotherapy in breast cancer patients significantly decreased right ventricular fractional area change from 48.3% to 42.1% and worsened right ventricular longitudinal strain.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: